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Abstract
The infusion of lipid emulsions allows a high energy supply, facilitates
the prevention of high glucose infusion rates and is indispensable for
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andshouldbeprovidedwiththeusualPNtopreventdepletionofessen-
Working group for
developing the
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may be reasonable. The recommended daily dose for parenteral lipids
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Zusammenfassung
Die Infusion von Lipidemulsionen erlaubt die Zufuhr einer hohen Ener-
giedichte,ermöglichtdieVermeidunghoherGlukoseinfusionsratenund
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Germany ist unverzichtbar für die Bedarfsdeckung mit essentiellen Fettsäuren.
Zur Vermeidung eines Mangels an essentiellen Fettsäuren ist die Gabe 4 Dept. of Medicine, Univ. of
Hamburg;currentlyatBaxter von Lipidemulsionen innerhalb ≤7 Tage nach Beginn der PE (parenter-
alenErnährung)erforderlich.EinefettarmePEmithoherGlukosezufuhr Schweiz AG, Zuerich,
Switzerland erhöht das Risiko für eine Hyperglykämie. Bei parenteral ernährten
Patienten mit Neigung zur Hyperglykämie sollte eine Erhöhung des 5 Dept. of Anaesthesiology,
Intensive Medicine and Verhältnisses zwischen Lipid- und Glukosezufuhr erwogen werden. Bei
kritisch Kranken sollte die Glukosezufuhr auf nicht mehr als etwa 50% Special Pain Therapy,
Landshut, Germany derEnergiezufuhrbegrenztwerden.Lipidemulsionenmiteinerniedrigen
Phospholipid/Triglyzerid-Ratio werden empfohlen und sollten mit der 6 Dept. Surgery I, St. Mary's
Hospital Witten, Germany üblichen PE verabreicht werden, um einer Verarmung an essentiellen
Fettsäuren vorzubeugen, das Risiko stark erhöhter Blutzuckerwerte zu
vermindern und eine verstärkte Hepatosteatose zu vermeiden. Biolo-
gischaktivesVitaminE(α-Tocopherol)sollteregelmäßigzusammenmit
Lipidemulsionen zugeführt werden, um einer Lipidperoxidation vorzu-
beugen. Die parenterale Lipidzufuhr sollte in der Regel etwa 25–40%
der parenteralen Nicht-Protein-Energiezufuhr betragen. In bestimmten
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Review Article OPEN ACCESS Special IssueSituationen (z.B. bei kritisch Kranken, respiratorisch insuffizienten Pa-
tienten) kann eine Fettzufuhr bis zu 50 oder 60% parenteraler Nicht-
Protein-Energiezufuhr sinnvoll sein. Die empfohlene Tagesdosis für die
parenterale Gabe von Lipidemulsionen bei Erwachsenen liegt bei
0,7–1,3 g Triglyzeride/kg KG. Die Serum Trigylzeridkonzentrationen
sollten regelmäßig kontrolliert werden, um eine Dosisreduktion bei Tri-
glyzeridkonzentrationen >400 mg/dl (>4,6 mmol/l) und eine Unterbre-
chung der Lipidinfusion bei >1000 mg/dl (>11,4 mmol/l) vornehmen
zu können. Auswirkungen der Auswahl aus den verschiedenen verfüg-
baren Lipidemulsionen sind derzeit nicht eindeutig belegt.
Schlüsselwörter: Fettemulsionen, alpha-Tocopherol, hepatische
Steatose, mehrfach ungesättigte Fettsäuren, kritisch Kranke
Background
The infusion of lipid emulsions allows for high energy
supply with iso-osmolar solutions. In addition, an ad-
equateproportionoftheenergyintakeaslipidsfacilitates
the prevention of high glucose infusion rates and can,
therefore,contributetothepreventionofhyperglycaemia
andhepaticsteatosis.Lipidemulsionsarealsoindispens-
able for supplying the requirements of essential fatty
acids.
The quantitatively dominant lipids in enteral and paren-
teral nutrition are triglycerides (triacylglycerols, neutral
lipids; gylcerol esterified with three fatty acids). The
physical, chemical and metabolic properties of trigly-
ceridesaredeterminedbytheirfattyacidcontents.Based
ontheirchainlength,fattyacidsareconsideredasshort-
chain (<8 carbon atoms), medium-chain (8–10 carbon
atoms), intermediate-chain (12–14 carbon atoms) and
long-chain (≥16 carbon atoms) fatty acids, which can
either be saturated (without double bonds) or mono- or
polyunsaturated. Saturated, monounsaturated and poly-
unsaturated fatty acids differ in their metabolic and
physiologicalproperties.Whilesaturatedfattyacidsserve
primarilyasanenergysource,polyunsaturatedfattyacids
playanimportantroleascomponentsofstructurallipids,
for example in biological membranes. Polyunsaturated
fattyacidsofthen-6series(linoleicacidandmetabolites),
andpolyunsaturatedfattyacidsofthen-3series(α-linolen-
ic acid and metabolites) cannot be synthesised de novo
by higher organisms and are, thus, essential nutrients.
For healthy adults the recommended dietary intake of
linoleic acid is 2.5% and of α-linolenic acid is 0.5% of the
energyintake[1].Long-chainpolyunsaturatedfattyacids
formed from the essential fatty acids, linoleic acid and
α-linolenic acid, are important components of cell mem-
brane and markedly affect numerous membrane proper-
ties such as their fluidity, transport processes, and the
activity of membrane-anchored proteins and receptors.
They also modify gene expression by binding to nuclear
receptors like PPAR. Certain polyunsaturated fatty acids
(dihomo-gamma-linolenicacid,20:3n-6;arachidonicacid,
20:4n-6; eicosapentaenoic acid, 20:5n-3) serve as pre-
cursorsinthesynthesisofeicosanoids.Then-6fattyacid
arachidonicacidisaprecursorofpro-inflammatorymedi-
ators (such as leukotrienes of the n-4 series), and of
prostaglandinsandthromboxanesofthen-2series,which
increasethevasculartoneandpromoteplateletaggrega-
tion. In contrast, prostaglandins and thromboxanes of
the n-3 series and leukotrienes of the n-5 series, formed
fromthen-3fattyacideicosapentaenoicacid,havemany
antagonisticeffectssuchasareductioninplateletaggre-
gation and vascular tone as well as anti-inflammatory
effects.
More recently novel lipid mediators derived from poly-
unsaturated fatty acids with pro-resolving activities on
inflammatory processes have been identified. They were
identified in exsudates from resolving inflammation and
comprisethelipoxins,resolvins,andprotectins(forreview
see [2], [3]). Their synthesis is favored by the transcrip-
tionalup-regulationofneutrophil15-LObyPGE2andPGD2,
the so-called “eicosanoid switch” [4]. They are highly
stereospecific and act in the pico- to nanomolar range
[5], [6]. They affect PMN recruitment and trafficking, ex-
pression of pro-inflammatory genes, reduce leukocyte-
mediated tissue injury, and take part in chemokine re-
moval.
Lipoxins
Lipoxins are derived from AA and are generated through
different biosynthetic pathways. Cells rich in 15-lipoxy-
genase (15-LO) like airway epithelial cells, macrophages
and basophils oxidize AA to 15S-HETE that is further
converted by neutrophil 5-LO to an epoxytetraene inter-
mediate from which LXA4 and LXB4 are formed. Alterna-
tively, these lipoxins can also be generated from LTA4 by
platelet 12-LO, most preferably under conditions of hyp-
oxia and diminished platelet glutathione content.
In addition, lipoxins can be generated from 15-HETE
stored in membrane inositol-containing lipids. Upon re-
lease, 15-HETE instead of AA is processed by neighbour-
ing leukocytes resulting in decreased leukotriene and
increased lipoxin formation.
In the presence of aspirin, COX-1 is inhibited and COX-2
is acetylated. In vascular endothelial and in epithelial
cells, acetylated COX-2 metabolizes AA to 15R-HETE that
is then processed by neutrophil 5-LOX to the aspirin-
triggered lipoxins (ATLs) 15-epi-LXA4 and 15-epi-LXB4.
These epimers are more stable than the LXA4 and LXB4
due to slower enzymatic degradation.
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Adolph et al.: Lipid emulsions – Guidelines on Parenteral Nutrition, ...Figure 1: Eicosanoids synthesis pathways. Depending on the fatty acid content of cellular membranes lipid mediators with
different pro-inflammatory potency or pro-resolving properties are generated from omega-3 or omega-6 polyunsaturated fatty
acids via the cyclooxygenase or lipoxygenase pathway. Pro-inflammatory arachidonic acid (AA)-derived 5-series leukotrienes,
2-series prostanoids, and thromboxane A2 and eicosapentaenoic acid derived 3-series prostanoids and 5-series leukotrienes
withlargelyreducedinflammatoryproperties.Pro-reslovinglipoxinsderivefromAAwhileresolvinsandprotectinsaregenerated
from EPA.
BothLXA4andATLbindtotheALX/FPRL1-receptor,which
leads to reduced agonist-induced superoxide production
of PMNs and also inhibits their migration [7]. In addition,
lipoxins regulate CD11/CD18 expression and L-selectin
shedding[8].Ontheotherhand,theyincreasemonocyte
recruitment and uptake of apoptotic PMNs by macro-
phages [9].
Resolvins and protectins
The resolvins and protectins are derived from the
omega-3fattyacidsEPAandDHAbydifferentbiosynthetic
pathways (Figure 1). Only resolvins of the E1-series are
generated from EPA through the tandem transcellular
conversion of EPA by acetylated COX II in vascular endo-
thelial and epithelial cells and LOX in activated neutro-
phils.Alternatively,resolvinE1(RvE1)canbesynthesized
independent from aspirin by cytochrome P450
monooxygenase [10].
Resolvins of the D-series (RvD1) and protectins (PD1,
NPD1) are derived from DHA by biosynthetic pathways
involving LOX. In addition, via aspirin-acetylated COX II,
aspirin-triggered RvD1 (AT-RvD1) can be generated.
RvE1 is a ligand of the orphan receptor ChemR23 acting
and inhibits NF-κB activation [11]. In addition, RvE1 is a
partial agonist at the LTB4-receptor BLT1 on PMNs and
dampens LTB4-dependent activation of PMNs as shown
by reduced mobilization of intracellular calcium by RvE1
compared to LTB4 [12]. In addition, RvE1 dose-depend-
ently inhibited LTB4-induced calcium mobilization.
RvE1 dramatically reduced neutrophil infiltration in
zymosan-induced peritonitis in mice that was BLT1-de-
pendent at low but independent at high RvE1 concentra-
tions [12]. Furthermore, RvE1 blocked PMN superoxide
generation[13]andreducedtheexpressionofproinflam-
matory genes.
Also, resolvins of the D-series block production of pro-in-
flammatory mediators as shown in the case of TNF-α-in-
ducedgenerationofIL-1βinmicroglialcells[14].Further-
more,theyregulatePMNinfiltrationintoinflamedtissues
[14], [15], [16].
Like resolvins, protectins regulate PMN infiltration as
demonstrated by reduced peritoneal PMN recruitment in
a mouse model [6]. PD1 exerts its actions also when ad-
ministered after the initiation of inflammation and was
shown to act in an additive fashion together with RvE1.
Furthermore, PD1/NPD1 has profound neuroprotective
actionsasevidencedbythelimitationofbraininjuryafter
stroke.Inthiscontext,Lukiwandcoworkersdemonstrated
that protection by NPD1 from oxidative stress-mediated
injury mainly occurs through the modulation of apoptotic
signaling pathways [17].
PD1 exerts immunoregulatory effects as it blocks T-cell
migration, secretion of TNFα and IFN-γ, and promotes T-
cell apoptosis via clustering of lipid rafts [18], [19]. Fur-
thermore, in concert with lipoxins and resolvins, it in-
creases CCR5 expression on apoptotic PMNs thereby
promoting removal of CCR5L and termination of the in-
flammatory reaction [20].
Characteristicsoflipidmetabolism
in critically ill patients
Endogenous lipid stores are the main energy source for
critically ill patients with an inadequate food intake. In
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lyzed to release free fatty acids and glycerol into the cir-
culation [21]. The markedly increased mobilisation of
free fatty acids results in a decrease in intracellular
triglyceridestorage.Thisincreasedlipidcatabolismisnot
counteredbyparenteraladministrationofcarbohydrates.
Usually, the released free fatty acids are rapidly utilised
inperipheraltissues.Dependingontheoverallmetabolic
situation, there is either ketone body formation or re-es-
terification and triglyceride formation in the liver, sub-
sequentlyreleasedintothecirculationasverylowdensity
lipoproteins (VLDL). The increase in plasma levels of free
fatty acids is proportional to the severity of the trauma,
and the extent to which the production of free fatty acids
surpasses their utilisation.
• Fat-free parenteral nutrition can result in subnormal
serum levels of essential fatty acids within one week
(IIb)
• Administration of lipid emulsions is required within no
more than one week after starting PN (C).
Commentary
Total PN with carbohydrate and amino acid solutions but
without lipid emulsions results in a biochemically detect-
able deficiency of essential fatty acids, with a drop in
linoleic acid and a rise in the trien/tetraen ratio, within
only one week ([22]; IIb). These deficiencies can be cor-
rected by parenteral administration of lipid emulsions
[23]. In infants, not only biochemical but also clinical
signs of essential fatty acid deficiency, such as scaly
dermatitis,canbeseenafterjustoneweekoffat-freePN
([24], [25], [26]; Ib).
• Low-fat PN with a high glucose intake increases the
risk of hyperglycaemia (Ia)
• In parenterally fed patients with a tendency to hyper-
glycaemia,anincreaseinthelipid-glucoseratioshould
be considered (C).
Commentary
Tappyetal.[27]randomisedcriticallyillpatientstoeither
PN with 75% glucose, 15% amino acids and 10% lipid
energyintakeorPNwith70%lipid,15%glucoseand15%
amino acid energy intake. The low lipid intake was asso-
ciated with increased blood glucose levels (Ia).
Thetypicalmetabolicchangesresultingfromthesystemic
inflammatoryreactionischaracterizedbyreducedcarbo-
hydrate and increased lipid oxidation. Therefore, an in-
creased exogenous carbohydrate intake enhances the
risk of hyperglycaemia.
In a randomised study of polytrauma patients, there was
a significantly higher rate of infection in patients admin-
isteredparenteralsoybeanoilemulsionwithanextremely
high non-protein energy intake of 28 kcal/kg compared
to patients who received no intravenous lipids over the
first few days [28]. However, it is noteworthy that the
energyintakeinpatientsgivenfat-freenutritionwas25%
lower,hencecomplicationsmightalsohaveresultedfrom
excessive overall substrate supply. In contrast, a meta-
analysis of studies in surgical patients showed no differ-
ences in the course of the illness and rate of complica-
tionswithPNeitherwithorwithoutlipidemulsionsadmin-
istered [29].
Effectsofparenterallipidadministration
on glucose metabolism
In healthy patients, both the plasma glucose concentra-
tionandtheglucoseuptakebytissuesremainedunaffect-
ed by simultaneous parenteral infusion of glucose (4
mg/kg/min,usingtheglucose-clamptechnique)andlipid
emulsions(20%soybeanoilor20%soybeanoil/medium-
chain triglycerides (MCT)) at an infusion rate of 0.07
g/kg/h). However, both lipid emulsions reduced glucose
oxidation as compared to the control group ([30], IIa).
Incriticallyillpatients,oxidativeandnon-oxidativeglucose
utilisation (continuous glucose administration,
2 mg/kg/min, plus amino acid administration, 0.15 g
N/kg/day) is not influenced by the simultaneous admin-
istration of lipid emulsions (1 mg/kg/day, 20% soybean
oil emulsion) (indirect calorimetry, (1-
13C)-glucose,
(6.6-
2H2)-glucose)([31],IIa).Anincreaseinglucoseintake
(4 mg/kg/min) does not result in a decrease in endogen-
ous glucose production or gluconeogenesis in critically
illpatients.Ascomparedtolipid-dominatedPN(only15%
of the total calories are administered as glucose, rest as
20% soybean oil emulsion) no decrease in net protein
loss was achieved by a glucose intake of 4 mg/kg/min.
Tappy et al. [27] suggested that in critically ill patients
glucose should not exceed 50% of the parenteral energy
intakeduetothepotentialdetrimentaleffectsofpredom-
inantly glucose-based PN, such as enhanced insulin se-
cretion,potentialinsulinresistance,andhighCO2produc-
tionresultingfromthestimulationofthede-novolipogen-
esis.
Liver damage
Inadultpatientswithgastrointestinaldisorders,adminis-
trationofPNcontainingsoybeanoil,whichprovidedeither
2.5% or 30% of non-protein energy over a two-week
period, did not result in significant differences in ALT
(alanine transferase), AST (aspartate transferase) and
alkaline phosphatase between the two groups ([32]; Ib).
In critically ill patients, an excessive intake of glucose in-
creases hepatic lipogenesis [33], [34], [35], [36],
whereas intravenous lipids reduce the dependency on
glucose as an energy source. A case study showed that
intravenouslipidadministrationloweredhepaticsteatosis
[37]. Animals receiving lipid-free PN demonstrated an
increase in hepatic steatosis, and in ALT and AST as
compared to PN with lipids [38].
The impact of PN with or without lipids on hepatic ste-
atosis was tested in a randomised controlled study on
37 patients (22 men). The patients received their non-
protein energy intake either from glucose only or from
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extremely high amino-acid low-carbohydrate intake [39].
Over a period of 11–13 days of PN, the liver fat content,
measured in repeated biopsies, increased from 5% to
35%intheglucosegroup(p<0.001)andfrom7%to23%
(p<0.001) in the amino acid group, whereas the group
receivinglipidemulsionsshowednoincreaseinsteatosis.
The accumulation of fat in the liver was associated with
raised levels of serum ALT and AST, but no cholestatic
changes.
Development of cholestatic liver disease associated with
PN has been frequently observed in premature infants
withsepticinfections[38].CasestudiessuggestthatPN-
associatedcholestasisinchildrenreceivinglong-termPN
canbeimprovedbyreducingorinterruptingtheparenteral
lipid intake [40]. However, in adults receiving long-term
nutrition(>6months)thedegreeofcholestasiscorrelated
with the energy supply, and not with the proportion of fat
to energy provided ([41], IIb). In a pilot study carried out
on 14 patients, a slight increase in liver size, and in the
sonographically detected echodensity of the liver was
detected in patients receiving soybean oil emulsion for
one week, whilst no significant changes were observed
in patients given soybean oil/MCT emulsion. General
conclusions can not be deduced as there were methodo-
logical limitations of this study.
The occurrence of cholestasis has been associated with
increased serum concentrations of phytosterols that are
found in vegetable oils and in lipid emulsions [42], [43].
In newborn pigs, phytosterols reduced bile flow [44].
However, it remains controversial whether the increased
phytosterol serum levels in cholestatic PN patients are a
cause or an effect of cholestasis [42], [43].
Osmolarity/peripheral venous
application
• Lipid emulsions can be infused via peripheral veins
over a number of days (C).
Commentary
Due to their low osmolarity (20% lipid emulsions:
270–345 mosm/l; 350–410 mosm/kg), lipid emulsions
can be infused via peripheral venous access if needed.
• The infusion of lipid emulsions presents no independ-
ent, clinically relevant risk of infection (IV).
Commentary
In vitro studies suggested that the infusion only of 10%
lipid emulsions resulted in significantly larger bacterial
proliferation within 6–24 hours than the use of mixed PN
solutions with or without lipids, after experimental inocu-
lation with Staph. aureus, Strept. pyogens, Str. faecalis,
Escherichia coli, Pseudomonas aeruginosa, Klebsiella
pneumonia [45], [46], [47], [48]. In contrast, a clinical
study in newborns found bacterial contamination of the
infusion solution to occur after 24 or 48 hours, irrespect-
iveofwhethermixturescontainlipidsornot[49].Although
theinvitromultiplicationofCandidaalbicanswassimilar
in all infusion solutions [45], [46], in a clinical study con-
tamination in lipid emulsions was higher after 24 hours
than after 48 hours ([49]; IIb). A case-control study,
however, showed that post-operative infections or febrile
episodes associated with the infusion of lipid-based
hypnotic propofol were due to insufficient aseptic tech-
niques during the administration of the infusion [50]. A
lowerriskofcontaminationhasbeenreportedincomplete
mixtures used for PN than in the infusion of individual
componentswithaddedlipidsolutions[46],[51].Ameta-
analysisofstudiesinsurgicalpatientsshowednoassoci-
ation of infectious complications with the administration
of parenteral lipid emulsions [29].
Lipid infusion, lipid peroxidation and
anti-oxidants
• Biologically active vitamin E (α-tocopherol) should
continuously be administered along with parenteral
lipid emulsions (B).
Commentary
Administration of polyunsaturated fatty acids results in
an increase in lipid peroxidation markers (malonyldialde-
hyde, TBARS), with a corresponding drop in the concen-
trationofα-tocopherolinpatientsreceivingPNcontaining
soybeanoilemulsion([52];IIb;[53];Ib).Inpatientsreceiv-
ing home PN, an administration of 500 ml of 20% soy-
bean oil emulsion plus 10 IU α-tocopherol (two to three
times a week) resulted in stable plasma α-tocopherol
levels, whereas tissue levels of α-tocopherol dropped
steadily([54],IIa).DailysupplementationofPNcontaining
a soybean oil/MCT mixed emulsion with 100 mg DL-α-
tocopherolresultedinhighervitaminEserumconcentra-
tions and lower in vitro peroxidation of VLDL and LDL
particles ([55]; Ib). Current soybean oil/MCT emulsions
contain 0.85 mg α-tocopherol/g triglyceride. PN with an
olive oil/soybean oil emulsion resulted in lower concen-
trations of lipid peroxidation markers and higher vitamin
E serum levels than with a soybean oil emulsion ([56];
Ib; [53]; Ib).
• Intravenous lipids should usually be provided with PN
(C).
Commentary
A lipid emulsion should usually be provided with PN to
prevent depletion of essential fatty acids, lower the risk
of hyperglycaemia, and prevent hepatic steatosis. If PN
is indicated, lipid emulsions should commence after
hemodynamicstabilityhasbeenestablishedorachieved.
• Parenteral lipids should provide about 25–40% of the
parenteral non-protein energy supply (C).
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Basedontherecommendationsoffoodintakeforhealthy
persons[1]andbyclinicalexperience,itisrecommended
that parenteral lipids should usually provide about
25–40% of non-protein calories, depending on the indi-
vidual patient’s tolerance to carbohydrates and lipids. In
critically ill patients, a higher lipid intake of up to 50% of
the non-protein calories may be advisable, in view of fre-
quentlyalteringmetabolicstateandglucoseintolerance.
In intensive care patients with respiratory insufficiency,
up to 60% of non-protein energy is administered as lipid
to patients with good lipid tolerance during the acute
phase, with the objective to reduce the intensity of
mechanical ventilation caused by diminished carbon di-
oxide production (RQ<0.8).
Huschak et al. [57] observed a significant reduction in
CO2 production, and in the duration of mechanical venti-
lation in mechanically ventilated poly-trauma patients,
when given 60% of overall energy intake as intravenous
lipidsascomparedtothecontrolgroupthatreceivedonly
30% of energy as lipids (Ib).
• The recommended daily dose for parenteral lipids in
adults is between 0.7 and 1.3 g triglycerides/kg body
weight, but this can be increased to 1.5 g/kg body
weight in case of high energy requirements (C).
Commentary
Fatty acids are oxidised in hepatocytes, myocardium,
skeletalmuscles,andothertissues.Alipidsupplygreater
than the maximum rate of lipid oxidation, estimated
between 1.2 and 1.7 mg/kg/min in adults, is not recom-
mended. ‘Fat Overload Syndrome’ may result when lipid
infusion rate is too high relative to the rate of utilisation.
Non-utilised lipid particles can be taken up by the mono-
nuclear phagocyte system (MPS), and the immune de-
fence might deteriorate, as a result of inadequate
chronic activation of the MPS [58], [59]. The clinical
symptoms of ‘Fat Overload Syndrome’ are similar to sys-
temicinflammatoryresponsesyndrome(SIRS)orsepsis:
fever, hepatosplenomegaly, icterus, acute lung injury
(ALI/ARDS), thrombocytopenia, bleeding, disseminated
intravascularcoagulation,metabolicacidosisandhypoal-
buminaemia.
• In patients receiving parenteral lipids, a serum trigly-
cerideconcentration>400mg/dl(>4.6mmol/l)should
result in a dosage reduction, and a serum triglyceride
concentration >1000 mg/dl (>11.4 mmol/l) should
lead to an interruption of lipid infusion (C).
Commentary
While a fasting serum triglycerides <200 mg/dl is desir-
able in healthy individuals, serum triglyceride levels of
approximately 4.6 mmol/l (400 mg/dl) can be reached
postprandially and are considered acceptable during in-
fusion of lipid emulsions (C).
Hypertriglyceridemiainducedbylipidinfusioncanusually
becontrolledbyreducingthedose[60];IIb).Ifhypertrigly-
ceridemia (TG >4.6 mmol/l or >400 mg/dl) occurs with
continuous infusion, the lipid emulsion dose should be
reduced, and in cases of severe hypertriglyceridemia (TG
>11.4 mmol/l or >1000 mg/dl) the dose should be inter-
rupted[61],[62].Duringthefirstdaysofinfusion,plasma
triglyceride levels should be monitored so that the dose
can be modified, if necessary. When lipid utilisation is
impaired, e.g. in severe illness, insulin resistance or liver
failure,thelipiddoseshouldbeadaptedbasedonplasma
triglyceride concentrations. Determination of serum
opacity in the supernatant after centrifugation of whole
blood is not considered useful.
• Lipid infusion with PN is not indicated in severe hyper-
lipidemia (e.g. hereditary or acquired disorders of
triglyceride hydrolysis), in severe metabolic acidosis
with impaired lipid utilisation, and in severe coagulo-
pathy (DIC stage III or higher) (C).
Commentary
Organfailure,disturbancesinmicrocirculationafterblood
transfusions, or disturbances in coagulation present no
absolute contraindication for parenteral lipid administra-
tion. Parenteral supply of 20% soybean oil emulsions
(35% of an overall energy supply of 35–40 kcal/kg/day)
resulted in no impairment in pulmonary hemodynamics,
gas exchange and diffusion capacity in patients after
major upper abdominal surgery ([63]; Ib).
• In acutely ill patients, lipid infusion should be admin-
isteredoveratleast12hours/day.Withamorecritical
metabolic situation, slower infusion rates such as
continuous infusion over approximately 24 hours are
recommended. Shorter infusion times may be chosen
in stable patients, particularly those receiving long-
term or home PN (C).
Commentary
In ARDS patients, a randomised study comparing intake
of 1.3 g lipid emulsion/kg body weight over either 6 or
24 hours showed a disadvantage with the rapid infusion
rate as evaluated by pulmonary prostaglandin metabol-
ism, pulmonary shunt and oxygenation index ([64]; Ib).
• The use of lipid emulsions with a low phospho-
lipid/triglyceride ratio is recommended (B).
Commentary
Emulsions with low a phospholipid/triglyceride ratio,
usually in 20% lipid emulsions, result in less hyperlip-
idemia than emulsions with a higher phospholipid/trigly-
ceride ratio (classic 10% emulsions) ([65], [66], [67],
[68]; Ib)
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Soybean oil emulsions
Parenteral lipid emulsions based on soybean oil have
been widely used for several decades. Soybean oil con-
tains high concentrations of polyunsaturated fatty acids
(PUFA,around60%ofthetotalfattyacids;ratiooflinoleic
acid(n-6)toα-linolenicacid(n-3)approximately8:1).The
administration of soybean oil emulsions resulted in high
serum PUFA concentrations. However, due to the low
content of biologically active vitamin E (α-tocopherol),
serum vitamin E levels are lower without added supple-
ments than with an olive oil-based emulsion, which has
a higher vitamin E/PUFA ratio ([56]; Ib; [53]; Ib).
Clinical, ex-vivo and animal studies suggested that the
type of parenterally administered fatty acids may influ-
ence immune functions, and high PUFA containing lipid
emulsions are associated with immunosuppressive ef-
fects ([69], [70], [71], [72]; Ib). Higher post-operative
concentrations of IL6 and CRP were seen after adminis-
trationofsoybeanoilemulsion(20%oftheenergyintake
in extremely high NPE intake of 40 kcal/kg daily) as
compared to lipid-free PN, in patients after resection of
gastriccolorectaltumours([73];IIa).Manyauthorsadvise
nottoadminister100%soybeanoilemulsionstocritically
ill patients [64], [73], [74], [75].
Emulsions based on a physical mix of
soybean oil and medium-chain
triglycerides (MCT)
An emulsion based on a physical mix of equal parts of
soybean oil and MCT-oil (from coconut oil) supplies only
half the PUFA as compared to 100% soybean oil emul-
sions,withasimilarratiooflinoleicacid(n-6)toα-linolen-
ic acid (n-3) of approximately 8:1. This lower essential
fatty acid supply is adequate for meeting the needs of
adults and infants [22], [76], [77], [78] (Ib). Although in
vitro hydrolysis of medium-chain triglycerides by lipopro-
tein lipase is faster than that of long-chain triglycerides,
clinicalstudiesdonotdemonstrateuniformresults.Some
studiesalsoreportslowerplasmaeliminationorincreased
serum triglycerides with soybean/MCT than with 100%
soybean oil emulsions [79], [80], probably due to differ-
ences in rate of lipid particle clearance in vivo [81].
Compared to LCT, MCT are rapidly taken up by mitochon-
dria, largely independent of carnitine, and are oxidised
fasterandtoagreaterproportion,buttheenergycontent
per g MCT fat is lower than of LCT. In an ex vivo test with
cross-over design, neutrophils showed reduced bacter-
icidal activity after infusion of soybean oil emulsions but
not after a mixed soybean oil/MCT emulsion [71]. The
administration of mixed soybean oil/MCT emulsion led
to a slight improvement in nitrogen balance of intensive
care patients after 6 and 9 days of PN ([82]; IIb), and in
septicpatientsafter10daysofPN([83];Ib)ascompared
to 100% soybean oil emulsion. In patients after stem cell
transplantationsformalignanthaematologicaldisorders,
the use of the mixed soybean oil/MCT emulsion (n=18)
resulted in a higher number of days with pyrexia (10
versus 7, p=0.01), and days on antibiotics (12 versus 8,
p=0.04) as compared to a 100% soybean oil emulsion
(n=18).Otherendpoints,suchastheoccurrenceofGraft
versus Host Disease (GVHD) and mortality, were not dif-
ferent ([84]; Ib). The use of an experimental soybean
oil/MCTemulsionina25/75ratioresultedinsignificantly
higher resting energy consumption, oxygen consumption
and carbon dioxide production, as a result of higher
thermogenetic effect of MCT as compared to a 100%
soybean oil emulsion [85]. The MCT/LCT emulsion avail-
able for clinical use has a lower proportion of MCT and
thus a lower thermogenic effect is expected.
Randomly interesterified MCT/soybean
oil emulsions
These emulsions contain triglyceride particles with re-
esterification of medium-chain fatty acids (made of
coconut oil) and long-chain fatty acids (made of soybean
oil) in random distribution within the molecule. The fatty
acid composition is comparable to that of the physical
mix of soybean oil and MCT. These randomly interesteri-
fied emulsions are often called “structured lipids”, al-
though they actually do not contain true structured lipids
with defined positions of specific fatty acids in the trigly-
ceride molecule [86]. Lindgren et al. [87], reported a
slightly higher positive nitrogen balance in intensive care
patientswithinthefirstthreedaysofreceivinganinfusion
of a randomly interesterified MCT/soybean oil emulsion
as compared to a 100% soybean oil emulsion (II). Ran-
domlyinteresterifiedlipids(1.0or1.5g/kg/day)resulted
inahigheroveralllipidoxidationrate(indirectcalorimetry)
inpost-operativepatientswithoutanincreaseinketogen-
esis or a difference in serum triglyceride levels when
compared to a soybean oil emulsion ([88], Ib). Although
Chambrier et al. [89] found no difference in nitrogen
balanceand3-methylhistidineexcretioninpost-operative
patients who received the physical mix or the randomly
interesterified mix of soybean oil and MCT, Kruimel et al.
[90]reportedanimprovednitrogenbalanceoverthefirst
5 post-operative days and a slight increase in the serum
triglyceridesandnon-esterifiedfattyacidsinpatientswho
were operated for an aortic aneurysm. Rubin et al. [91]
reportedsimilarsafetyandcompatibilityparameters,but
with faster normalisation of raised transaminases with
randomly interesterified soybean oil/MCT emulsion in
patients receiving home PN (Ib).
Olive oil/soybean oil
Theavailableoliveoilbasedlipidemulsioncontainsolive
oil and soybean oil in a ratio of 4:1, and shows a high
content of the monounsaturated oleic acid and of bio-
logicallyactivevitaminE(α-tocopherol).Theratiobetween
linoleic acid (n-6) and α-linolenic acid (n-3) is 9:1.
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bean oil emulsion in terms of observed numbers of
catheter infections, thromboses, and unplanned stays in
hospitalduringlong-termadministrationofover6months
([92];IIb).Inaninvitrotestofperipheralwhitebloodcells
from healthy persons, olive oil showed less influence on
the proliferation of lymphocyte subpopulations and their
receptorexpressionthansoybeanoilemulsions[93],and
similareffectswereshowninmonocytesandneutrophils
[94], [95]. A small group of 2x11 burns patients showed
an improvement in liver function when given parenteral
olive oil emulsions as compared to a soybean oil/MCT
group ([96]; Ib). In randomised controlled studies in chil-
dren and infants, the olive oil based emulsion showed
comparable tolerance and safety to a soybean oil emul-
sion, but resulted in more favourable fatty acid levels in
serum,reducedmarkersoflipidperoxidation,andhigher
serum vitamin E levels ([56]; Ib; [53]; Ib).
Fish-oil based emulsions
Incriticallyillpatients,thegenerationofpro-inflammatory
lipid mediators can be reduced with the use of fish oil
emulsions, which may prevent the escalation of SIRS to
sepsis or even septic shock [97], [98]. An infusion of fish
oil emulsion in healthy volunteers resulted in a reduction
intheinvitroreleaseofendotoxin-inducedpro-inflamma-
tory mediators like TNF-α, IL1, IL6 and IL8 from mono-
cytes ([75]; Ib). Morlion et al. [99] and Koeller et al. [100]
found a lower ratio of leukotriene B5 to leukotriene B4
inpost-operativepatientsafishoilemulsion,withpossible
anti-inflammatoryeffects(Ib).Schauderetal.[101]repor-
ted no immunosuppressive effects but an increase in
IFN-γ, TNF-α and IL-2 synthesis (Ib) after 0.2 g/kg/day of
parenteral fish oil in the post-operative phase (Ib).
Parenteralsupplementationwithfishoilemulsioninpost-
operative patients results in a rapid increase in the ratio
of eicosapentaenoic acid (20:5n-3; EPA) to arachidonic
acid (20:4n-6; AA) in thrombocyte phospholipids ([102],
Ib). A delay in collagen-induced, but not ADP-induced
platelet aggregation did not result in altered bleeding
times or bleeding complications following oesophagus
resections. Patients after major abdominal surgery, who
received either a soybean oil emulsion or a mixture of
20% fish oil emulsion and 80% soybean oil emulsion,
showed no clinically significant difference in coagulation
or bleeding times ([103]; Ib). Lower mortality, shorter
mechanical ventilation times, and shorter stays in inten-
sive care units and hospitals were reported in post-
operative patients, especially if the fish oil infusion had
been administered prior to surgery ([104]; Ib). The stable
HLA-DRexpressionpatternsobservedwhenreceivingfish
oil were associated with less severe infections [104].
Lower levels of ALT/AST, bilirubin, LDH and lipase were
alsoreportedincancerpatientsafterelectiveabdominal
surgerywhenamixtureof20%fishoilemulsionand80%
soybean oil emulsion was used as compared to 100%
soybean oil emulsion ([105]; Ib).
Theuseoffishoilemulsionin56patientswithabdominal
sepsis was associated with lower rates of re-operation
and shorter length of stay in the intensive care units and
total hospital stay ([106], abstract only). In an open case
analysis of 661 patients, increasing fish oil dosage was
advantageous for survival in 276 patients with sepsis
and 118, 80 and 17 patients with either 1, 2 or 3 organ
failures respectively ([107]; IIb). Parenteral fish-oil en-
riched lipid emulsion did not effect platelet function in
critically ill patients ([108]; Ib).
The high unsaturated fatty acid content in fish oil tends
undergo peroxidation, both during storage and in the
patient after infusion. Apart from the direct effects of re-
leased oxygen radicals, lipid peroxidation products have
apro-inflammatoryeffect.Peroxidationofthehighunsat-
urated fatty acids in the fish oil emulsions should be
preventedbyadditionofvitaminE(15–29.6mg/100ml).
MCT, soybean and fish oil based
emulsion
An emulsion of MCT-oil (coconut)/soybean oil/fish oil
(weightratio5:4:1)administeredtopatientsafterelective
major abdominal surgery for a 5-day duration reduced
the ratio of leukotriene B4/B5 in leukocytes stimulated ex
vivoascomparedtoasoybeanoilemulsion[100].Apost-
hoc analysis on a subgroup of 256 patients after abdom-
inal surgery in a multicentre trial reported a 5-day reduc-
tion in the postoperative length of hospital stay with
MCT/soybean/fish oil (5:4:1) as compared to soybean
oil emulsion, although the rate of clinically relevant com-
plications were similar [109]. In a very small group of 8
kidney donors and transplant recipients, infusion of this
lipidemulsioninducednodifferencesincoagulation,liver
orrenalfunctionsorserumcreatinineintransplantrecipi-
ents[110].Thecurrentlyavailablepublishedclinicaldata
on the use of this emulsion is still limited.
Emulsion of soybean oil, MCT, olive oil
and fish oil
A soybean/MCT/olive/fish oil emulsion in a weight ratio
of 30:30:25:15 in healthy volunteers (20% emulsion,
0.125g/kg/h),after6hoursofparenteralinfusion,resul-
ted in a slight rise in serum triglycerides and respectively
quicker clearance after discontinuing the appropriate
lipid emulsion as compared to a 20% soybean oil emul-
sion [111]. A published study of 249 postoperative pa-
tients showed that the rise in serum triglyceride levels,
when receiving this mixed lipid emulsion, is the same as
with a soybean oil emulsion [112]. In an interim evalu-
ationofasmallnumberofsurgicalpatientswhoreceived
5-days of postoperative PN, a reduction in hospital stay
of7dayswasrecordedinpatientsafteramixedemulsion
(13.4±2.0 days, n=19) than after a soybean oil emulsion
(20.4±10 days, n=14) [113]. Recent publication of the
data of all 249 patients in this study, however, did not
show any significant difference in the biochemical and
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theintention-to-treatanalysisortheper-protocolanalysis
[112]. Furthermore, there was an increased ex vivo re-
leaseofleukotrieneB5andreducedleukotrieneB4-release
from leukocytes [114]. In a small group of intensive care
patients (a total of 20 patients), it was found that there
was an increase in ALT in both groups after 5 days of PN
in a comparison between mixed emulsions and soybean
oilemulsions.Therewas,however,lesstendencytowards
an increase in the mixed emulsion group (n.s.) ([115];
Ib). The currently available published clinical data on the
use of this emulsion is still limited.
Conclusions
Soybean oil-based emulsions meet energy and essential
fattyacidrequirements.Thereareindicationsthatmixture
of soybean oil with other oils such as MCT or olive oil
result in more favourable metabolic parameters and a
moredesirable,lowerPUFAsupply.Emulsionscontaining
fish-oil may provide anti-inflammatory effects and offer
the potential for a targeted approach in specific disease
states. Further research is needed on relevant clinical
end points, and clear recommendations on clinical use
of different emulsions cannot be given at this time.
Notes
This article is part of the publication of the Guidelines on
Parenteral Nutrition from the German Society for Nutri-
tional Medicine (overview and corresponding address
under http://www.egms.de/en/gms/2009-7/000086.
shtml).
English version edited by Sabine Verwied-Jorky, Rashmi
Mittal and Berthold Koletzko, Univ. of Munich Medical
Centre, Munich, Germany.
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